Radiation boosts new drug against tough lymphoma?

NCT ID NCT06867536

Recruiting now Disease control Sponsor: Liling Zhang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding a short course of radiation to the drug glofitamab can help people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have large tumors. About 40 adults in China will receive glofitamab plus radiation. The main goal is to see how many achieve complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glofitamab (a bispecific antibody) and hypofractionated radiotherapy
What this could lead to: If successful, this combination could improve complete remission rates for patients with hard-to-treat DLBCL who have large tumors.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply broadly. The added radiotherapy may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.